Immunocore, one of UK biotech's brightest hopes ... anticipated to gain approval in late 2017/ early 2018. The privately-held, Oxford-based company says ImmTAC molecules offer a huge competitive ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a ...

Mizuho lowered the firm’s price target on Immunocore (IMCR) to $33 from $38 and keeps a Neutral rating on the shares. The firm’s thesis on Immunocore remains unchanged, and while Mizuho views ...

Immunocore Holdings IMCR has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...

Immunocore has a mixed history of earnings surprises. The company beat on earnings in two of the trailing four quarters while ...

NASDAQ:IMCR opened at $28.80 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The company has a fifty day moving average of $30.08 ...

In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against other stocks that are receiving the most insider investment in March. “The economy is ...

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X ...